LSHTM expert comments about NICE approval of the first long-acting injectable HIV treatment

The National Institute for Health and Care Excellence (NICE), an oversight body for the NHS has issued guidance recommending long-acting injectable HIV-1 treatment. The recommendation of cabotegravir with the drug rilpivirine could be a new treatment option for people suffering from HIV-1 whose antiretroviral medications have kept the virus at a lower amount and there isn’t any suspected viral resistance and no previous failure of other medications to treat HIV-1.

Professor Alison Grant, Dean of Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine said that the news was very exciting and could increase access to life-changing treatments for many. Modern antiretroviral therapy has helped millions of people living with HIV live normal life, healthy ones. They usually use a couple of tablets every day. It’s great to know that this will be a new option in the range of antiretroviral treatment options for people living with HIV in the UK, as some individuals have difficulty taking tablets regularly due to difficult circumstances, including the stigma around HIV, or not having secure accommodation and nowhere to store their medication. It is important to remember that this recommendation comes from NICE and that clinics still have a lot to do before they can administer these injections. This will likely take a few months.

Content Source:

Gemma Wilson

Gemma is a journalism graduate with keen interest in covering business news – specifically startups. She has as a keen eye for technologies and has predicted quite a few successful startups over the last couple of years.

Related Articles